| Lancet attempts to dispel concerns, concluding side-effects are rare Related items from OnMedica Overview of risk assessment and statin therapy Investigation backs BMJ in statins row Reducing threshold for statins even further might be cost-effective Statins might not cut colorectal cancer risk after all Statins controversy prompted patients to stop treatment |
No comments:
Post a Comment